Richard Wilson

Richard Wilson is currently the VP of Program Management & Portfolio Strategy at Astellas Gene Therapies. Richard has been with the company since April 2020 and in their current role, they are responsible for leading the Gene Therapy Program Management function and developing the portfolio of AAV-delivered genetic medicines. Richard has also redesigned the Core Team and Extended Team model from candidate nomination to launch, alongside a revamp of internal governance for decision-making on programs across Astellas Gene Therapies (AGT) divisions and their interfaces with Astellas.

In addition to their current responsibilities, Richard has also served as a key cross-divisional, cross-functional member of the AGT Center of Excellence Leadership Team and coordinated corporate-level planning and reporting, including the creation of objectives, performance tracking, and quarterly review meetings with the Astellas executive committee (EC). Richard also set up and co-chaired the AGT Implementation Office, which is accountable to the Astellas EC, and drove integration strategy and execution across the legacy Audentes business, including shared service structures for G&A functions.

Richard Wilson has a Master of Business Administration (M.B.A.) from the University of California, Berkeley, Haas School of Business with a focus in finance and leadership. Richard also has a B.Sc. (Hons) in Chemistry from The University of Manchester and is certified by LinkedIn in uncovering unconscious bias in recruiting and interviewing.

Their manager is Natalie Holles, President & CEO. They work with Catherine Parham - VP, Medical Affairs, Chris Lorenz - SVP, Technical Operations, and Mathew Pletcher - SVP, Research.